Shares of Pharvaris (NASDAQ:PHVS - Get Free Report) shot up 4.3% during mid-day trading on Thursday . The stock traded as high as $16.65 and last traded at $16.70. 13,304 shares traded hands during trading, a decline of 81% from the average session volume of 71,180 shares. The stock had previously closed at $16.01.
Wall Street Analyst Weigh In
Separately, JMP Securities increased their target price on Pharvaris from $46.00 to $55.00 and gave the stock a "market outperform" rating in a report on Friday, January 31st.
Read Our Latest Stock Report on PHVS
Pharvaris Stock Performance
The business's 50 day moving average price is $17.13 and its two-hundred day moving average price is $19.13. The company has a market capitalization of $877.95 million, a price-to-earnings ratio of -6.00 and a beta of -3.02.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of PHVS. Public Employees Retirement System of Ohio acquired a new position in Pharvaris during the third quarter worth $57,000. JPMorgan Chase & Co. boosted its holdings in Pharvaris by 1,125.3% during the fourth quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company's stock valued at $59,000 after purchasing an additional 2,847 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new position in Pharvaris during the fourth quarter worth $64,000. Barclays PLC acquired a new position in Pharvaris in the third quarter valued at about $106,000. Finally, KLP Kapitalforvaltning AS bought a new stake in Pharvaris during the 4th quarter worth approximately $111,000.
Pharvaris Company Profile
(
Get Free Report)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.
Read More
Before you consider Pharvaris, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharvaris wasn't on the list.
While Pharvaris currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
